Literature DB >> 2659888

Endothelial cell behavior after denudation injury is modulated by transforming growth factor-beta1 and fibronectin.

J A Madri1, M A Reidy, O Kocher, L Bell.   

Abstract

Endothelial denudation injury after endarterectomy, autologous and synthetic grafting and balloon angioplasty leads to exposure of thrombogenic vessel wall material and may elicit an atherogenic response in the media of the affected vessels in which complete reendothelialization may not occur. While the role(s) of extracellular matrix composition and organization in this process are only incompletely understood, it is widely accepted that endothelial cells respond to matrix components in specific, complex fashions. In this report we demonstrate that large vessel endothelial cell migration is affected by the surrounding matrix and the soluble factor, transforming growth factor-beta1, which may mediate its effects, in part, by modulating endothelial cell matrix synthesis. Specifically, large vessel endothelial cell migration is decreased on a fibronectin substratum and in the presence of transforming growth factor-beta1, which increases fibronectin mRNA and protein accumulation in culture. Inhibition of sheet migration is also elicited by the addition of soluble fibronectin to the cultures. These in vitro findings are consistent with our in vivo findings of increased staining of fibronectin luminally and in the intima in the chronically deendothelialized region of a balloon catheter denuded carotid artery. Thus, reendothelialization after iatrogenic and natural injury appears to be a complex process which can be modulated by the underlying matrix and soluble factors, which may themselves modulate the matrix synthesis of local vascular cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2659888

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  29 in total

1.  Dynamics of Vascular Remodeling: An Overview and Bibliography.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

2.  TGF-β and Smad3 modulate PI3K/Akt signaling pathway in vascular smooth muscle cells.

Authors:  Pasithorn A Suwanabol; Stephen M Seedial; Fan Zhang; Xudong Shi; Yi Si; Bo Liu; K Craig Kent
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-23       Impact factor: 4.733

3.  Alternative splicing of endothelial cell fibronectin mRNA in the IIICS region. Functional significance.

Authors:  O Kocher; S P Kennedy; J A Madri
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

Review 4.  Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects.

Authors:  Ian Toma; Timothy A McCaffrey
Journal:  Cell Tissue Res       Date:  2011-05-31       Impact factor: 5.249

5.  Transient functional expression of alphaVbeta 3 on vascular cells during wound repair.

Authors:  R A Clark; M G Tonnesen; J Gailit; D A Cheresh
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

6.  Immunohistochemical study of fibronectin in experimental myocardial infarction.

Authors:  W Casscells; H Kimura; J A Sanchez; Z X Yu; V J Ferrans
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

Review 7.  VLA-4 and lymphocyte trafficking in immune-inflammatory states: novel therapeutic approaches in allograft arteriopathy.

Authors:  S Molossi; M Rabinovitch
Journal:  Springer Semin Immunopathol       Date:  1995

8.  Fibronectin expression correlates with U937 cell adhesion to migrating bovine aortic endothelial cells in vitro.

Authors:  I A Hauser; E Setter; L Bell; J A Madri
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

9.  Vascular cells respond differentially to transforming growth factors beta 1 and beta 2 in vitro.

Authors:  J R Merwin; W Newman; L D Beall; A Tucker; J Madri
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

10.  Fibronectin expression in the normal and hypertrophic rat heart.

Authors:  W S Mamuya; P Brecher
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.